| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PAELR; EDNRBL; hET(B)R-LP |
| WB Predicted band size | 67 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human GPR37 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于GPR37抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Characterization of a novel antibody against the extracellular domain of GPR37 and its application in Parkinson's disease models*
**作者**：Smith A, et al.
**摘要**：本研究开发了一种特异性靶向GPR37胞外结构域的新型抗体，验证其在帕金森病小鼠模型中检测GPR37蛋白表达的能力，揭示了GPR37在黑质纹状体通路中的异常表达与疾病进展的相关性。
---
2. **文献名称**：*GPR37-specific antibodies as tools for studying receptor localization and function in glioblastoma cells*
**作者**：Chen L, et al.
**摘要**：通过免疫荧光和Western blot验证了两种GPR37抗体的特异性，证明其在胶质母细胞瘤细胞系中定位GPR37膜表达的功能，并发现GPR37高表达与肿瘤侵袭性相关。
---
3. **文献名称**：*Development of a sensitive ELISA using anti-GPR37 antibodies for detecting cerebrospinal fluid biomarkers in neurodegenerative disorders*
**作者**：Yamamoto K, et al.
**摘要**：报道了一种基于GPR37抗体的高灵敏度ELISA检测方法，用于定量分析阿尔茨海默病和帕金森病患者脑脊液中的GPR37水平，提示其作为神经退行性疾病潜在生物标志物的价值。
---
**备注**：以上文献信息为示例性质，实际引用时需核对真实来源及细节。如需具体文献，建议通过PubMed或Web of Science以“GPR37 antibody”为关键词检索最新研究。
GPR37. also known as the parkin-associated endothelin-like receptor (PAEL-R), is a class A G protein-coupled receptor (GPCR) predominantly expressed in the central nervous system, particularly in oligodendrocytes, astrocytes, and subsets of neurons. It features a long extracellular N-terminal domain and seven transmembrane helices, though its endogenous ligands remain partially characterized. Proposed ligands include prosaposin and head activator peptides, which may regulate GPR37 signaling in neurodevelopment and homeostasis.
GPR37 has garnered attention for its potential role in neurological disorders. It interacts with parkin, an E3 ubiquitin ligase linked to autosomal recessive Parkinson’s disease (PD), and its accumulation due to misfolding is implicated in PD pathogenesis. Additionally, GPR37 is associated with Alzheimer’s disease, neuroinflammation, and glioblastoma, where it may influence tumor progression and apoptosis.
Antibodies targeting GPR37 are critical tools for studying its expression, localization, and function. These antibodies—often monoclonal or polyclonal, derived from rabbits or mice—enable techniques like Western blotting, immunohistochemistry, and immunofluorescence. Validation in knockout models or siRNA-treated cells is essential to confirm specificity, given GPCRs’ structural similarities. Reliable GPR37 antibodies have facilitated discoveries in disease models, highlighting its potential as a biomarker or therapeutic target. However, challenges persist in elucidating its precise signaling mechanisms and ligand-receptor interactions, underscoring the need for continued research using well-validated reagents.
×
